Key result
ACE inhibitors protect against progressive renal injury over standard antihypertensives by lowering glomerular capillary pressure.
Why the study?
The progression of renal disease may be influenced by intraglomerular hemodynamics, and the therapeutic benefit of converting-enzyme inhibition in this context requires clarification.
Does converting-enzyme inhibitor therapy prevent progressive renal injury compared to other antihypertensive therapies?
Population
Experimental models and patients with progressive renal disease and systemic hypertension
Comparison
Converting-enzyme inhibitor therapy vs antihypertensive therapy not reducing glomerular capillary pressure
Design
Review
Authors
Loading...
May support preferential converting-enzyme inhibitor use for renal risk beyond BP control; leaves open randomized confirmation of outcomes.
Does converting-enzyme inhibitor therapy prevent progressive renal injury compared to other antihypertensive therapies?
Converting-enzyme inhibitors offer specific renoprotective benefits beyond systemic blood pressure control by selectively reducing glomerular capillary pressure.
Anderson et al. (1988) conducted a review in Progressive Renal Disease. Converting-enzyme inhibitor therapy vs. Antihypertensive therapy was evaluated on Glomerular injury / progressive renal injury. Converting-enzyme inhibitor therapy selectively reduces glomerular capillary pressure and protects against progressive renal injury, unlike standard antihypertensive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: